HIPAA Alert: Potential Data Breach Learn More

NCT/Study#

6717347 /

LYM 281

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP Versus R- CHOP in Participant With Previously Untreated Diffuse Large B- Cell Lymphoma (DLDCL) (waveLINE-010)

DISEASE GROUP:
Lymphoma
current phase:
Phase III
STUDY STATUS:
Enrolling
Location:
Belleville
For More information:

Call (201) 518-3587